Search Results - "Emeis, J. J."

C-Reactive Protein in Healthy Subjects: Associations With Obesity, Insulin Resistance, and Endothelial Dysfunction: A Potential Role for Cytokines Originating From Adipose Tissue? by Yudkin, John S, Stehouwer, C.D.A, Emeis, J.J, Coppack, S.W

“…C-reactive protein, a hepatic acute phase protein largely regulated by circulating levels of interleukin-6, predicts coronary heart disease incidence in…”
Get full text

Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: Progressive, interrelated, and independently associated with risk of death by STEHOUWER, Coen D. A, GALL, Mari-Anne, TWISK, Jos W. R, KNUDSEN, Elisabeth, EMEIS, Jef J, PARVING, Hans-Henrik

“…In 328 type 2 diabetic patients followed for 9.0 years (mean), we investigated whether endothelial dysfunction and chronic inflammation (estimated from plasma…”
Get full text

Use of fibrinolytic agents in the prevention of postoperative adhesion formation by Hellebrekers, B W, Trimbos-Kemper, T C, Trimbos, J B, Emeis, J J, Kooistra, T

“…To review the events leading to the formation of adhesions, to describe the development of fibrinolytic agents, to review more than a century of research on…”
Get more information

Increased levels of soluble vascular cell adhesion molecule 1 are associated with risk of cardiovascular mortality in type 2 diabetes: the Hoorn study by Jager, A, van Hinsbergh, V W, Kostense, P J, Emeis, J J, Nijpels, G, Dekker, J M, Heine, R J, Bouter, L M, Stehouwer, C D

“…Increased levels of soluble vascular cell adhesion molecule 1 are associated with risk of cardiovascular mortality in type 2 diabetes: the Hoorn study. A Jager…”
Get full text

von Willebrand Factor, C-Reactive Protein, and 5-Year Mortality in Diabetic and Nondiabetic Subjects: The Hoorn Study by Jager, Agnes, van Hinsbergh, Victor W. M, Kostense, Piet J, Emeis, Jef J, Yudkin, John S, Nijpels, Giel, Dekker, Jacqueline M, Heine, Robert J, Bouter, Lex M, Stehouwer, Coen D. A

“…Increased levels of von Willebrand factor (vWf) and C-reactive protein (CRP) predict cardiovascular mortality in selected populations. It is uncertain whether…”
Get full text

No Effect of C-Reactive Protein on Early Atherosclerosis Development in Apolipoprotein E3-Leiden/Human C-Reactive Protein Transgenic Mice by Trion, A, de Maat, M P.M, Jukema, J W, van der Laarse, A, Maas, M C, Offerman, E H, Havekes, L M, Szalai, A J, Princen, H M.G, Emeis, J J

“…OBJECTIVE—C-reactive protein (CRP) has been associated with risk of cardiovascular disease. It is not clear whether CRP is causally involved in the development…”
Get full text

Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE3-Leiden transgenic mice: Evidence for antiinflammatory effects of rosuvastatin by KLEEMANN, Robert, PRINCEN, Hans M. G, EMEIS, Jef J, JUKEMA, J. Wouter, FONTIJN, Ruud D, HORREVOETS, Anton J. G, KOOISTRA, Teake, HAVEKES, Louis M

“…Statins can exert anti-inflammatory antiatherosclerotic effects through an anti-inflammatory action, independent of lowering cholesterol. We addressed the…”
Get full text

Simvastatin improves disturbed endothelial barrier function by VAN NIEUW AMERONGEN, Geerten P, VERMEER, Mario A, NEGRE-AMINOU, Pascale, LANKELMA, Jan, EMEIS, Jef J, VAN HINSBERGH, Victor W. M

“…Recent clinical trials have established that inhibitors of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase (statins) reduce the risk of acute…”
Get full text

Endothelial dysfunction and low-grade inflammation and the progression of retinopathy in Type 2 diabetes by Spijkerman, A. M. W., Gall, M.-A., Tarnow, L., Twisk, J. W. R., Lauritzen, E., Lund-Andersen, H., Emeis, J., Parving, H.-H., Stehouwer, C. D. A.

“…Aims  To study whether microalbuminuria, endothelial dysfunction and low‐grade inflammation are associated with the presence and progression of diabetic…”
Get full text

Plasma concentration of C-reactive protein is increased in Type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction : evidence for chronic inflammation by SCHALKWIJK, C. G, POLAND, D. C. W, VAN DIJK, W, KOK, A, EMEIS, J. J, DRÄGER, A. M, DONI, A, VAN HINSBERGH, V. W. M, STEHOUWER, C. D. A

“…Moderately increased plasma concentrations of C-reactive protein are associated with an increased risk of cardiovascular disease. C-reactive protein, its…”
Get full text

Dietary sphingolipids lower plasma cholesterol and triacylglycerol and prevent liver steatosis in APOE3Leiden mice by Duivenvoorden, Ilse, Voshol, Peter J, Rensen, Patrick CN, Duyvenvoorde, Wim van, Romijn, Johannes A, Emeis, Jef J, Havekes, Louis M, Nieuwenhuizen, Willem F

“…BACKGROUND: The prevalence of dyslipidemia and obesity resulting from excess energy intake and physical inactivity is increasing. The liver plays a pivotal…”
Get full text

central roles of obesity-associated dyslipidaemia, endothelial activation and cytokines in the Metabolic Syndrome--an analysis by structural equation modelling by Chan, J.C.N, Cheung, J.C.K, Stehouwer, C.D.A, Emeis, J.J, Tong, P.C.Y, Ko, G.T.C, Yudkin, J.S

“…Hypothesis: The multi-faceted components of the metabolic syndrome now include markers of inflammation and endothelial activation. Despite this growing body of…”
Get full text

Effect of Low Dose Atorvastatin Versus Diet-Induced Cholesterol Lowering on Atherosclerotic Lesion Progression and Inflammation in Apolipoprotein E3–Leiden Transgenic Mice by Verschuren, Lars, Kleemann, Robert, Offerman, Erik H, Szalai, Alexander J, Emeis, Sjef J, Princen, Hans M.G, Kooistra, Teake

“…OBJECTIVE—To evaluate whether low-dose atorvastatin suppresses atherosclerotic lesion progression and inflammation in apolipoprotein E*3 (apoE*3)–Leiden mice…”
Get full text

Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women by van Baal, W M, Kenemans, P, van der Mooren, M J, Kessel, H, Emeis, J J, Stehouwer, C D

“…To study the short-term effect of unopposed oestradiol (E2) and sequentially combined hormone replacement therapy (E2 + P) on C-reactive protein (CRP) in…”
Get more information

Interaction of an annexin V homodimer (Diannexin) with phosphatidylserine on cell surfaces and consequent antithrombotic activity by Kuypers, Frans A, Larkin, Sandra K, Emeis, Jef J, Allison, Anthony C

“…Annexin V (AV), a protein with anticoagulant activity, exerts antithrombotic activity by binding to phosphatidylserine (PS), inhibiting activation of serine…”
Get more information

Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo-controlled 12-week study by van Baal, W M, Emeis, J J, van der Mooren, M J, Kessel, H, Kenemans, P, Stehouwer, C D

“…In this randomised, placebo-controlled 12-week study, sixty healthy postmenopausal women received either placebo (N = 16) or daily 2 mg micronised oestradiol,…”
Get more information

Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women by van Baal, W M, Kenemans, P, Emeis, J J, Schalkwijk, C G, Mijatovic, V, van der Mooren, M J, Vischer, U M, Stehouwer, C D

“…To study the effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity. Prospective, randomized, controlled…”
Get more information

Regulation of the acute release of tissue-type plasminogen activator from the endothelium by coagulation activation products by Emeis, J J

Get more information

The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in Type II diabetic subjects by YUDKIN, J. S, PANAHLOO, A, STEHOUWER, C, EMEIS, J. J, BULMER, K, MOHAMED-ALI, V, DENVER, A. E

“…Improved glycaemic control might reduce both microvascular and macrovascular complications of Type II diabetes (non-insulin-dependent) mellitus. To explore…”
Get full text

The effects of sex steroids on plasma levels of marker proteins of endothelial cell functioning by van Kesteren, P J, Kooistra, T, Lansink, M, van Kamp, G J, Asscheman, H, Gooren, L J, Emeis, J J, Vischer, U M, Stehouwer, C D

“…We studied thirteen male-to-female (M-->F) and ten female-to-male (F-->M) transsexuals who, for four months, received cross-sex treatment with, respectively,…”
Get more information